|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/14/21 Bionovate Technologies Corp. 8-K:5 7/09/21 1:17K Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 12K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 9, 2021
| BIONOVATE TECHNOLOGIES CORP. |
| (Exact name of registrant as specified in its charter) |
| Nevada |
|
| 33-1229553 | |
| (State or other jurisdiction |
| (Commission |
| (IRS Employer |
| (Address of principal executive offices) | (Zip Code) |
Registrant s telephone number, including area code: (280) 231-1606
Gewerbestrasse 10, Cham, Switzerland 6330
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| None | None | None |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 9, 2021, Aleksander Vucak resigned as a director and as an officer of our company. Mr. Vucak’s resignation was not the result of a disagreement between Mr. Vucak and our company on any matter relating to our company’s operations, policies or practices. On July 9, 2021, Timothy Jones was appointed as a director to replace Mr. Vucak and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.
Mr. Jones, age 64, began his career at Bayer in 1983 as a sales manager after graduating in business at a university in the United Kingdom. Mr. Jones recently retired from his position at Bayer and is now pursuing different opportunities.
There are no family relationship between Mr. Jones and any director or executive officer of our company and no related party transactions required to be reported under Item 404(a) of Regulation S-K.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIONOVATE TECHNOLOGIES CORP. | |
| /s/ Timothy Jones | |
| President | |
| Date: July 14, 2021 |
| 3 |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/14/21 | None on these Dates | ||
| For Period end: | 7/9/21 | |||
| List all Filings | ||||